[go: up one dir, main page]

AU2001293373A1 - 2-guanidino-4-arylchinazolines as NHE-3 inhibitors - Google Patents

2-guanidino-4-arylchinazolines as NHE-3 inhibitors

Info

Publication number
AU2001293373A1
AU2001293373A1 AU2001293373A AU9337301A AU2001293373A1 AU 2001293373 A1 AU2001293373 A1 AU 2001293373A1 AU 2001293373 A AU2001293373 A AU 2001293373A AU 9337301 A AU9337301 A AU 9337301A AU 2001293373 A1 AU2001293373 A1 AU 2001293373A1
Authority
AU
Australia
Prior art keywords
arylchinazolines
nhe
guanidino
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001293373A
Inventor
Norbert Beier
Rolf Gericke
Claudia Wilm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2001293373A1 publication Critical patent/AU2001293373A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2001293373A 2000-04-18 2001-03-22 2-guanidino-4-arylchinazolines as NHE-3 inhibitors Abandoned AU2001293373A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10019062 2000-04-18
DE10019062A DE10019062A1 (en) 2000-04-18 2000-04-18 Use of known and new 2-guanidino-4-aryl-quinazoline derivatives as NHE-3 inhibitors useful for the treatment of e.g. hypertension, thrombosis, cardiac ischemia, peripheral and CNS ischemia
PCT/EP2001/003281 WO2001079186A1 (en) 2000-04-18 2001-03-22 2-guanidino-4-arylchinazolines as nhe-3 inhibitors

Publications (1)

Publication Number Publication Date
AU2001293373A1 true AU2001293373A1 (en) 2001-10-30

Family

ID=7639090

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001293373A Abandoned AU2001293373A1 (en) 2000-04-18 2001-03-22 2-guanidino-4-arylchinazolines as NHE-3 inhibitors

Country Status (18)

Country Link
US (1) US20040224965A1 (en)
EP (1) EP1274691A1 (en)
JP (1) JP2004501082A (en)
KR (1) KR20030011789A (en)
CN (1) CN1422260A (en)
AR (1) AR028914A1 (en)
AU (1) AU2001293373A1 (en)
BR (1) BR0109867A (en)
CA (1) CA2406161A1 (en)
DE (1) DE10019062A1 (en)
HU (1) HUP0300909A3 (en)
MX (1) MXPA02010264A (en)
NO (1) NO20024997L (en)
PL (1) PL356559A1 (en)
RU (1) RU2002130246A (en)
SK (1) SK13472002A3 (en)
WO (1) WO2001079186A1 (en)
ZA (1) ZA200209274B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10043667A1 (en) * 2000-09-05 2002-03-14 Merck Patent Gmbh 2-guanidino-4-aryl-quinazolines
CA2469385A1 (en) * 2001-12-05 2003-06-12 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them
US6911453B2 (en) 2001-12-05 2005-06-28 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them
DE10161767A1 (en) * 2001-12-15 2003-06-26 Merck Patent Gmbh New 2-guanidino-4-heterocyclyl-quinazoline derivatives, useful as sodium-proton antiporter subtype III inhibitors for treating e.g. respiratory, renal, ischemic or lipid metabolism disorders
DE10163239A1 (en) * 2001-12-21 2003-07-10 Aventis Pharma Gmbh Substituted imidazolidines, process for their preparation, their use as medicaments or diagnostic agents, and medicaments containing them
US20030187045A1 (en) 2001-12-21 2003-10-02 Uwe Heinelt Substituted imidazolidines, process for their preparation, and their use as a medicament or diagnostic
US6703405B2 (en) 2001-12-22 2004-03-09 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as a medicament, and medicament containing them
DE10163914A1 (en) * 2001-12-22 2003-07-03 Aventis Pharma Gmbh Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as medicament, and medicament containing them
DE10163992A1 (en) * 2001-12-24 2003-07-03 Merck Patent Gmbh 4-aryl-quinazolines
US7049333B2 (en) * 2002-06-04 2006-05-23 Sanofi-Aventis Deutschland Gmbh Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis
US20050054705A1 (en) 2003-02-04 2005-03-10 Aventis Pharma Deutschland Gmbh N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
DE10304374A1 (en) 2003-02-04 2004-08-05 Aventis Pharma Deutschland Gmbh Novel substituted 2-aminoimidazoles, process for their preparation, their use as medicament or diagnostic agent and medicament containing them
DE10341240A1 (en) 2003-09-08 2005-04-07 Aventis Pharma Deutschland Gmbh Substituted thienoimidazoles, process for their preparation, their use as medicament or diagnostic agent, and medicament containing them
DE102005001411A1 (en) 2005-01-12 2006-07-27 Sanofi-Aventis Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them
DE102005044817A1 (en) * 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them
WO2009006066A2 (en) 2007-06-28 2009-01-08 Sanofi-Aventis U.S. Llc Process for the preparation of benzimidazol thienylamine compounds and intermediates thereof
CA2735842A1 (en) 2008-09-02 2010-03-11 Sanofi-Aventis Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2748607A1 (en) 2008-12-31 2010-07-08 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US20120088737A2 (en) * 2009-10-02 2012-04-12 Ajinomoto Co., Inc Novel acyl guanidine derivatives
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
JP6392754B2 (en) 2012-08-21 2018-09-19 アーデリクス，インコーポレーテッド Compounds and methods for inhibiting NHE-mediated reverse transport in the treatment of fluid retention or salt overload related diseases and gastrointestinal diseases
MX382203B (en) 2013-04-12 2025-03-11 Ardelyx Inc NHE3 (SODIUM-HYDROGEN EXCHANGER 3) BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT.
MX375386B (en) 2014-07-25 2025-03-06 Taisho Pharmaceutical Co Ltd HETEROARYL-SUBSTITUTED PHENYLTETRAHYDROISOQUINOLINE COMPOUND.
EA201991676A1 (en) 2017-01-09 2020-01-30 Арделикс, Инк. NHE-MEDIATED ANTI-PORT INHIBITORS
WO2018129552A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
AU2018335130B2 (en) 2017-08-04 2023-02-16 Ardelyx, Inc. Glycyrrhetinic acid derivatives for treating hyperkalemia
CN114008065B (en) 2019-02-07 2025-03-11 阿德利克斯股份有限公司 Glycyrrhetinic acid derivatives for the treatment of hyperkalemia
EP3972599B1 (en) 2019-05-21 2025-10-22 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3131187A (en) * 1964-04-28 Certain z-guantoino-x-aryl-quinazolines

Also Published As

Publication number Publication date
WO2001079186A1 (en) 2001-10-25
BR0109867A (en) 2003-06-03
RU2002130246A (en) 2004-03-27
US20040224965A1 (en) 2004-11-11
HUP0300909A3 (en) 2004-01-28
ZA200209274B (en) 2004-02-16
AR028914A1 (en) 2003-05-28
NO20024997D0 (en) 2002-10-17
MXPA02010264A (en) 2003-04-25
CN1422260A (en) 2003-06-04
DE10019062A1 (en) 2001-10-25
KR20030011789A (en) 2003-02-11
HUP0300909A2 (en) 2003-10-28
PL356559A1 (en) 2004-06-28
SK13472002A3 (en) 2003-02-04
CA2406161A1 (en) 2002-10-16
EP1274691A1 (en) 2003-01-15
NO20024997L (en) 2002-10-17
JP2004501082A (en) 2004-01-15

Similar Documents

Publication Publication Date Title
AU2001293373A1 (en) 2-guanidino-4-arylchinazolines as NHE-3 inhibitors
AU2001258771A1 (en) -secretase inhibitors
AU2002219555A1 (en) VLA-4 Inhibitors
AU2001296961A1 (en) 17-beta-hydroxysteroid dehydrogenase-ii inhibitors
AU2001237041A1 (en) Kinase inhibitors
SI1686119T1 (en) Pyrimidine-5-one derivatives as LDL-PLA2 inhibitors
AU2001244399A1 (en) Gamma-secretase inhibitors
AU2002220241A1 (en) Parb inhibitors
AU2002356762A1 (en) 4-arylquinazolines and use thereof as nhe-3 inhibitors
AU2002211663A1 (en) Nf-$g(k)b inhibitors
AU6381701A (en) Bisamidino compounds as nhe-3 inhibitors
AU2001265089A1 (en) Rc-timer scheme
AU5248800A (en) Fading inhibitors
AU2001285750A1 (en) Urokinase inhibitors
AU2001294557A1 (en) Thrombin inhibitors
AU2001236052A1 (en) Urease inhibitors
AU2002211662A1 (en) Nf-kappab inhibitors
AU2002222627A1 (en) Tak1 inhibitors
AU2001220281A1 (en) Rollerboard for road-skiing
AU3235100A (en) Prothease inhibitors
AU2002224550A1 (en) Corrosion inhibitors
AU2001255408A1 (en) Tetrahydro-azepinone derivatives as thrombin inhibitors
AU2002222628A1 (en) Keratinocyte proliferation inhibitors
AU2001278997A1 (en) Thrombin inhibitors
AU2001233965A1 (en) Novel cd23 inhibitors